Prot# IM103027: Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial -- Extended Criteria Donors (BENEFIT-EXT) [Phase 3, Randomized, Partially-Blinded, Active-Controlled, Parallel-Group, Multicenter Clinical Trial]

Project: Research project

Project Details

StatusFinished
Effective start/end date6/15/0512/1/14

Funding

  • ICON Clinical Research, LLC (IM103027)
  • Bristol-Myers Squibb Company (IM103027)